Prof Jeffrey Cummings

Prof Jeffrey Cummings Scientific Advisory Board Jeffrey is a world-renowned Alzheimer’s researcher and leader of clinical trials. He is professor of Brain Sciences and Director of the Chambers-Grundy Center for Transformative Neuroscience, D...

Whitepaper: Risk-Based Quality Management (RBQM)

📄 About This Document Learn how Risk-Based Quality Management (RBQM) can enhance the quality, efficiency, and oversight of clinical trials. This one-pager outlines the key principles of RBQM, its core components, and insights from a case study...

Is MASH the most silent disease everyone is talking about?

Interview 3rd June 2025 Julius Clinical sat down with Professor Helena Cortez-Pinto (MD, PhD), a gastroenterology and hepatology specialist with a particular interest in steatotic liver disease, nutrition, and public health, to talk about metab...

Julius Clinical spoke to obesity expert Professor Liesbeth van Rossum about the multi-factorial, complex and often misunderstood disease and what the future holds

15 April 2025, The Netherlands Julius Clinical’s Scientific Officer, Associate Professor Manuel Castro Cabezas, interviewed Professor Liesbeth van Rossum, internist-endocrinologist and professor in the field of obesity at the Erasmus MC, Univ...

How hospital networks can optimise patient care, knowledge sharing and trial recruitment: a case study from the Dutch Thyroid Network

15 May 2025, The Netherlands Julius Clinical’s Scientific Officer, practising internist, and founding member of the Dutch Thyroid Network (Schildkliernetwerk - Home), Dr Manuel Castro Cabezas, was delighted to sit down with Dr Marco Medici, a...

Julius Clinical and Peachtree BioResearch Solutions Merge to Form a Fully Integrated Global CRO with Increased CNS Capabilities

Zeist, Netherlands, May 14, 2025– Julius Clinical, a leading full-service Contract Research Organization (CRO) headquartered in the Netherlands (Zeist), and Peachtree BioResearch Solutions, a specialized CNS CRO based in the United States (Georg...

Recruitment milestone achieved in important Phase II study in Alzheimer’s Disease

Julius Clinical are proud to announce the successful completion of recruitment for the PRImus-AD study, a clinical Phase II study which investigates the safety and efficacy of the drug candidate PRI-002 for the treatment of Alzheimer's Disease. ...

Regulatory Manager (in the Netherlands)

Clinical Team Lead (in the Netherlands)

Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk factors in rheumatoid arthritis

A paper published in Clinical Rheumatology from the research group of our Scientific Officer Manuel Castro Cabezas and Chief Scientific Officer Rick Grobbee indicates that patients with rheumatoid arthritis with high liver fibrosis scores are like...